Drug Profile
KHK 2805
Alternative Names: KHK2805Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Kyowa Hakko Kirin
- Developer Kyowa Kirin
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Folate receptor 1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Cancer in Japan (unspecified route) (Kyowa Kirin pipeline, September 2023)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Cancer in Japan
- 16 Apr 2016 Preclinical trials in Cancer in Japan (unspecified route) before April 2016